Friday, July 10, 2026
🇺🇸 FDA

Drug profile · INN

envafolimab

envafolimab is a programmed cell death 1 ligand 1 binding agent.

NMPA: clinical trials
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — envafolimab
Class
—
Route
—
Patents
0
Programs
4
Data quality
0.70
← All drugs Search patents Pipeline programs Drug news hub Event calendar

Quick answer

envafolimab is a programmed cell death 1 ligand 1 binding agent.

Key facts

INN envafolimab
Mechanism Programmed cell death 1 ligand 1 binding agent
Target Programmed cell death 1 ligand 1

Mechanism of action

Programmed cell death 1 ligand 1 binding agent

Primary target: Programmed cell death 1 ligand 1

Approval history

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. Donafenib + Envafolimab Phase 2 · Anhui Provincial Hospital · Hepatocellular Carcinoma
  2. Envafolimab Phase 2 · First People's Hospital · Gastric Cancer
  3. Envafolimab Phase 2 · First People's Hospital · Metastatic Colorectal Cancer
  4. Envafolimab Injection Phase 2 · First People's Hospital · Gastrointestinal Neoplasms

Related & competitor drugs

Browse all drugs
  1. atezolizumab Antineoplastic and immunomodulating agents (L01)
  2. avelumab Antineoplastic and immunomodulating agents (L01)
  3. cosibelimab-ipdl Programmed cell death 1 ligand 1 inhibitor
  4. durvalumab Antineoplastic and immunomodulating agents (L01)
  5. sugemalimab Antineoplastic and immunomodulating agents (L01)
  6. adebrelimab Programmed cell death 1 ligand 1 inhibitor

Frequently asked questions

What is envafolimab?

envafolimab is a programmed cell death 1 ligand 1 binding agent.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.